Genetic	O
predisposition	O
to	O
neuroblastoma	O
mediated	O
by	O
a	O
LMO1	B-ENHANCER
super	I-ENHANCER
-	I-ENHANCER
enhancer	E-ENHANCER
polymorphism	O
.	O


Neuroblastoma	O
is	O
a	O
paediatric	O
malignancy	O
that	O
typically	O
arises	O
in	O
early	O
childhood	O
,	O
and	O
is	O
derived	O
from	O
the	O
developing	O
sympathetic	O
nervous	O
system	O
.	O


Clinical	O
phenotypes	O
range	O
from	O
localized	O
tumours	O
with	O
excellent	O
outcomes	O
to	O
widely	O
metastatic	O
disease	O
in	O
which	O
long	O
-	O
term	O
survival	O
is	O
approximately	O
40	O
%	O
despite	O
intensive	O
therapy	O
.	O


A	O
previous	O
genome	O
-	O
wide	O
association	O
study	O
identified	O
common	O
polymorphisms	O
at	O
the	O
LMO1	O
gene	O
locus	O
that	O
are	O
highly	O
associated	O
with	O
neuroblastoma	O
susceptibility	O
and	O
oncogenic	O
addiction	O
to	O
LMO1	O
in	O
the	O
tumour	O
cells	O
.	O


Here	O
we	O
investigate	O
the	O
causal	O
DNA	O
variant	O
at	O
this	O
locus	O
and	O
the	O
mechanism	O
by	O
which	O
it	O
leads	O
to	O
neuroblastoma	O
tumorigenesis	O
.	O


We	O
first	O
imputed	O
all	O
possible	O
genotypes	O
across	O
the	O
LMO1	O
locus	O
and	O
then	O
mapped	O
highly	O
associated	O
single	O
nucleotide	O
polymorphism	O
(	O
SNPs	O
)	O
to	O
areas	O
of	O
chromatin	O
accessibility	O
,	O
evolutionary	O
conservation	O
and	O
transcription	O
factor	O
binding	O
sites	O
.	O


We	O
show	O
that	O
SNP	O
rs2168101	O
G	O
>	O
T	O
is	O
the	O
most	O
highly	O
associated	O
variant	O
(	O
combined	O
P	O
=	O
7	O
.	O
47	O
x	O
10	O
(	O
-	O
29	O
)	O
,	O
odds	O
ratio	O
0	O
.	O
65	O
,	O
95	O
%	O
confidence	O
interval	O
0	O
.	O
60	O
-	O
0	O
.	O
70	O
)	O
,	O
and	O
resides	O
in	O
a	O
super	B-ENHANCER
-	I-ENHANCER
enhancer	E-ENHANCER
defined	O
by	O
extensive	O
acetylation	O
of	O
histone	O
H3	O
lysine	O
27	O
within	B-ENHANCER
the	I-ENHANCER
first	I-ENHANCER
intron	I-ENHANCER
of	I-ENHANCER
LMO1	E-ENHANCER
.	O


The	O
ancestral	O
G	O
allele	O
that	O
is	O
associated	O
with	O
tumour	O
formation	O
resides	O
in	O
a	O
conserved	O
GATA	O
transcription	O
factor	O
binding	O
motif	O
.	O


We	O
show	O
that	O
the	O
newly	O
evolved	O
protective	O
TATA	O
allele	O
is	O
associated	O
with	O
decreased	O
total	O
LMO1	O
expression	O
(	O
P	O
=	O
0	O
.	O
028	O
)	O
in	O
neuroblastoma	O
primary	O
tumours	O
,	O
and	O
ablates	O
GATA3	O
binding	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O


We	O
demonstrate	O
allelic	O
imbalance	O
favouring	O
the	O
G	O
-	O
containing	O
strand	O
in	O
tumours	O
heterozygous	O
for	O
this	O
SNP	O
,	O
as	O
demonstrated	O
both	O
by	O
RNA	O
sequencing	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
and	O
reporter	O
assays	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
.	O


These	O
findings	O
indicate	O
that	O
a	O
recently	O
evolved	O
polymorphism	O
within	O
a	O
super	B-ENHANCER
-	I-ENHANCER
enhancer	I-ENHANCER
element	I-ENHANCER
in	I-ENHANCER
the	I-ENHANCER
first	I-ENHANCER
intron	I-ENHANCER
of	I-ENHANCER
LMO1	E-ENHANCER
influences	O
neuroblastoma	O
susceptibility	O
through	O
differential	O
GATA	O
transcription	O
factor	O
binding	O
and	O
direct	O
modulation	O
of	O
LMO1	O
expression	O
in	O
cis	O
,	O
and	O
this	O
leads	O
to	O
an	O
oncogenic	O
dependency	O
in	O
tumour	O
cells	O
.	O
